Kevin Lee Sells 5,967 Shares of Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,967 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total transaction of $29,297.97. Following the transaction, the chief executive officer directly owned 613,029 shares in the company, valued at $3,009,972.39. The trade was a 0.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, April 6th, Kevin Lee sold 1,716 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $5.05, for a total transaction of $8,665.80.

Bicycle Therapeutics Trading Down 3.2%

BCYC traded down $0.16 during trading on Monday, hitting $4.89. The company’s stock had a trading volume of 458,881 shares, compared to its average volume of 590,426. Bicycle Therapeutics PLC Sponsored ADR has a twelve month low of $4.24 and a twelve month high of $9.55. The firm’s 50 day moving average price is $5.33 and its 200-day moving average price is $6.57.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.71. The business had revenue of $47.96 million for the quarter, compared to analysts’ expectations of $7.08 million. Bicycle Therapeutics had a negative return on equity of 33.21% and a negative net margin of 301.66%. As a group, analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BCYC. Principal Financial Group Inc. grew its holdings in shares of Bicycle Therapeutics by 64.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock worth $8,889,000 after purchasing an additional 451,135 shares during the period. Long Focus Capital Management LLC lifted its position in Bicycle Therapeutics by 7.7% during the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after buying an additional 101,402 shares in the last quarter. Armistice Capital LLC lifted its position in Bicycle Therapeutics by 4.8% during the second quarter. Armistice Capital LLC now owns 2,800,000 shares of the company’s stock valued at $19,460,000 after buying an additional 128,000 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in Bicycle Therapeutics by 6.2% during the third quarter. Westfield Capital Management Co. LP now owns 2,952,543 shares of the company’s stock worth $22,853,000 after buying an additional 172,052 shares during the period. Finally, Brooklyn Investment Group purchased a new stake in Bicycle Therapeutics during the fourth quarter worth approximately $69,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on BCYC shares. Citizens Jmp lowered their price target on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Wednesday, March 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Needham & Company LLC lowered their target price on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Morgan Stanley reaffirmed a “sell” rating and set a $13.00 price target on shares of Bicycle Therapeutics in a research report on Tuesday, March 17th. Finally, Jefferies Financial Group raised shares of Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $14.50.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.